Home

Anthony J. Polverino

CIK 1729957 · Chief Scientific Officer · last filed 2026-05-20

Anthony J. Polverino is a Chief Scientific Officer who has filed 20 SEC Form 4 insider transactions across 2 companies since 2018. Across all open-market trades the lifetime net is −$36.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $885.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$885.4K

Companies

2

Total Filings

20

Lifetime Open-Market Net

-$36.6K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted Director 25,730 $0.75 $19.3K $0 8 2025-01-03
ZYME Chief Scientific Officer 36,407 $24.32 $885.4K -$36.6K 11 2022-01-07

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-20 — Grant (A) — $0
2025-01-03 BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted Grant (A) +24,000 $0 EDGAR
2022-02-03 BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted Grant (A) +3,882 $0 EDGAR
2022-01-07 ZYME Grant (A) +74 $1.0K EDGAR
2021-12-17 BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted Grant (A) +2,000 $0 EDGAR
2021-12-10 BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Delisted Grant (A) +4,216 $0 EDGAR
2021-09-02 ZYME Exer (M) +4,900 $73.5K EDGAR
2021-07-08 ZYME Grant (A) +454 $13.4K EDGAR
2021-03-12 ZYME Mixed +1,452 -$36.6K EDGAR
2021-01-11 ZYME Grant (A) +48 $1.5K EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.